Trial Search Results

A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

The purpose of this study is to test the safety and efficacy of RO6958688 in combination with atezolizumab in treating patients with advanced solid tumors. In Part I (Dose escalation/schedule finding), the study will test increasing doses of RO6958688 administered either weekly or once every three weeks with a fixed dose of atezolizumab administered once every three weeks. In Part II (Dose expansion), the study will look at safety and efficacy of RO6958688 in combination with atezolizumab at the determined dose and schedule in subjects with different levels of CEA-expression in their solid tumors.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting